CG Oncology reports Q2 2026 results, flags near-term PIVOT-006 data
The company reported a wider net loss and roughly $1.0 billion in cash while pointing to topline Phase 3 data and a fourth-quarter BLA milestone.
SEC filing
Latest
2 stories
Thursday, August 6
CG Oncology expands stock sale program to $1.05 billion
The company filed an amendment lifting its at-the-market offering capacity by $500 million after selling $550 million in shares under the original agreement.
SEC filing